uploads/2018/03/Chart-005-2-1.jpg

How AstraZeneca’s Respiratory Products Performed in 4Q17

By

Updated

Respiratory products

One of AstraZeneca’s (AZN) growth platforms is its respiratory products portfolio. During 4Q17, the respiratory segment reported revenues of $1.3 billion during 4Q17, 8% growth in operating revenues as compared to 4Q16. The growth was driven by strong sales from Pulmicort, Bevespi, Daliresp, Duaklir, and Tudorza/Eklira, and nearly flat operating revenues for Symbicort, partially offset by lower sales of other products. The below chart compares the revenues for key respiratory products.

Article continues below advertisement

Symbicort

Symbicort is one of AstraZeneca’s best-selling drugs. Symbicort saw revenues of $752 million during 4Q17, nearly flat revenues at constant exchange rates as compared to 4Q16. The revenues were driven by strong sales in the emerging markets and US markets, partially offset by lower sales from the European markets and established markets.

The US markets reported Symbicort sales of $288 million during 4Q17, a 1% increase in revenues as compared to 4Q16. Emerging markets reported Symbicort sales of $117 million during 4Q17, a 17% increase in operating revenues as compared to 4Q16. The European markets reported revenues of $229 million during 4Q17, a 7% decline in operating revenues as compared to 4Q16.

Symbicort is used for the treatment of asthma and chronic obstructive pulmonary disease (or COPD). Some other drugs that treat COPD include Novartis’s (NVS) Ultibro Breezhaler, Merck’s (MRK) Proventil HFA, GlaxoSmithKline’s (GSK) Seretide/Advair, and Boehringer Ingelheim’s Spiriva, Atrovent, and Combivent.

Article continues below advertisement

Pulmicort

Pulmicort reported revenues of $371 million during 4Q17, 26% growth in operating revenues as compared to 4Q16. The growth was driven by increased sales of Pulmicort in the emerging markets and the US markets, partially offset by lower sales of the drug in European markets and other established markets.

Pulmicort saw sales of $49 million in US markets during 4Q17, a 36% growth in revenues as compared to 4Q16. The emerging markets reported Pulmicort sales of $269 million during 4Q17, 34% growth in operating revenues as compared to 4Q16.

Other drugs

Other respiratory drugs from AstraZeneca’s portfolio are Bevespi, Daliresp, Duaklir, and Tudorza/Eklira. Daliresp reported revenues of $53 million in 4Q17, a 27% growth in operating revenues driven by increased sales of Daliresp in the US markets and European markets. Duaklir reported revenues of $23 million in 4Q17, a 16% increase in operating revenues driven by a strong performance in the European markets. Tudorza and Eklira reported revenues of $42 million during 4Q17, 11% growth in operating revenues due to strong sales in the US markets, European markets, and established rest of the world markets.

Advertisement

More From Market Realist